KRAS and neoplasm: For example, loss-of-function (LoF) alterations in TP53 reduce the anti-tumour infiltration of natural killer (NK) cells [6] while gain-of-function (GoF) alterations in KRAS promote pro-tumour infiltration of myeloid-derived suppressor cells [7].